Real-life effectiveness and safety of the inhalation suspension budesonide comparator vs the originator product for the treatment of patients with asthma : a historical cohort study using a US health claims database by Price, David B et al.
© 2017 Price et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Pragmatic and Observational Research 2017:8 69–83
Pragmatic and Observational Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
69
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/POR.S132839
Real-life effectiveness and safety of the 
inhalation suspension budesonide comparator 
vs the originator product for the treatment of 
patients with asthma: a historical cohort study 
using a US health claims database
David B Price1,2 
Eran Gefen3 
Gokul Gopalan4 
Cristiana Miglio2 
Rosie McDonald2 
Vicky Thomas2 
Simon Wan Yau Ming2
1Academic Primary Care, Division 
of Applied Health Sciences, 
University of Aberdeen, Aberdeen, 
UK; 2Observational and Pragmatic 
Research Institute, Singapore, 
Singapore;  3Teva Pharmaceuticals, 
Petach Tikva, Israel; 4Teva 
Pharmaceuticals, Frazer, PA, USA
Objective: The objective of this study was to determine whether the effectiveness of budesonide 
comparator is non-inferior to budesonide reference in the prevention of asthma exacerbations. 
Asthma-related hospitalizations and safety were also examined.
Methods: This study used a matched, historic cohort design. Data were drawn from the Clinfor-
matics™ Data Mart US claims database and included a 1-year baseline, starting 1 year before the 
index prescription date, and a 1-year outcome period. Patients received budesonide comparator or 
reference treatment. The primary outcome was the rate of asthma exacerbations. Non-inferiority 
for budesonide comparator vs budesonide reference was established if the 95% confidence interval 
(CI) upper limit of mean difference in proportions between treatments was <15%. Secondary 
outcomes examined rate of asthma-related hospitalizations and adverse events (AEs).
Results: The budesonide comparator and reference-matched cohorts each included 3109 
patients. The adjusted upper 95% CI for the difference in proportions of patients experienc-
ing asthma exacerbations was 0.035 (3.5%), demonstrating non-inferiority. Cohorts did not 
significantly differ in the rate of asthma exacerbations (adjusted rate ratio [RR]=1.04, 95% CI: 
0.95–1.14) or rate of asthma-related hospitalizations (adjusted RR=1.10, 95% CI: 0.99–1.24) 
after adjusting for baseline confounders. No asthma exacerbations occurred during the outcome 
period in 72.9% of budesonide comparator patients and 71.8% of budesonide reference patients. 
No asthma-related hospitalizations occurred in 77.9% of patients in the budesonide comparator 
cohort and 79.0% of patients in the budesonide reference cohort. The most frequent AEs were 
throat irritation (≤0.4% of patients) and hoarseness/dysphonia (0.02% of patients). AEs did not 
significantly differ between treatment cohorts.
Conclusion: In this real-life study, non-inferiority of the budesonide comparator vs reference 
was met for the primary end point of asthma exacerbation rates. Asthma-related hospitalization 
and AE rates did not differ between the two treatment cohorts. The budesonide comparator is 
an effective and safe treatment alternative for asthma exacerbations.
Keywords: generic/therapeutic use, exacerbation, hospitalization, asthma control, asthma 
medication
Introduction
According to the recent data, as many as 334 million people suffer from asthma 
worldwide.1 In the US alone, it is estimated that 22,648,000 people have asthma and 
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that the annual cost of this disease is ~$56 billion.2,3 Using 
nationally representative data for adults in the US from the 
2003 and 2005 Medical Expenditure Panel Surveys, it was 
estimated that the annual medication cost for an adult patient 
with asthma was ~US$1600 (in 2008) higher than that for a 
patient without asthma.4
Budesonide is the only nonhalogenated inhaled glucocor-
ticoid, and it has been used for asthma therapy for >35 years.5 
Budesonide inhalation suspension, used for the management 
of persistent asthma and for the treatment of asthma exacer-
bations,6,7 has demonstrated efficacy and safety in multiple 
clinical trials.6,8–10 A nebulized inhalation suspension of the 
corticosteroid budesonide, budesonide reference (Pulmicort 
Respules®; AstraZeneca LP, Wilmington, DE, USA), was the 
first medication of this type licensed in the US (approved by 
the US Food and Drug Administration [FDA], August 2000) 
for the long-term maintenance treatment of asthma,11 and the 
efficacy and safety of this preparation are supported by the 
results of multiple controlled clinical trials.12–16
The budesonide comparator (Budesonide Steri-Neb™; 
Teva Pharmaceuticals, Inc., Sellersville, PA, USA) is a 
generic version of the budesonide reference with the same 
active ingredient and was similarly approved in many coun-
tries for the treatment of asthma in 2009.17 The availability 
of a lower-cost treatment with efficacy equivalent to the 
budesonide reference would have potential economic benefit 
in reducing the cost of asthma care.
Asthma exacerbations represent a transient and increased 
worsening of asthma symptoms and are also associated with 
pulmonary function decline, reduced health status, and 
possibly premature mortality.18 Asthma exacerbations and 
hospitalizations are associated with significant morbidity, are 
important end points for the assessment of treatment, and are 
the major drivers of the overall cost of asthma care.19,20 The 
current study examined the real-life clinical management 
of US patients with asthma using a historic cohort study of 
patients enrolled in a health care claims database. The objec-
tive of this study was to determine whether the budesonide 
comparator is non-inferior in effectiveness to the budesonide 
reference in patients with asthma. Budesonide comparator 
vs reference safety was also examined.
Methods
Design
The study used the Clinformatics™ Data Mart (CDM) 
database, an anonymous patient longitudinal database (US 
observational data), that contains retrospective claims data 
(2000–2012) from an employed, commercially insured 
population that includes >45 million people. The database 
contains medical claims (primary care and secondary care), 
pharmacy claims, laboratory results, and pricing information.
A matched (1:1), historic cohort design was used to 
compare the budesonide comparator treatment cohort to 
the budesonide reference treatment cohort (Figure 1). The 
budesonide comparator cohort included two groups of 
patients: initiation patients and change patients. The initia-
tion patients were not prescribed corticosteroid nebulizers 
during baseline and received their first prescription for the 
budesonide comparator at the index prescription date. The 
change patients were using budesonide reference (250, 500, 
or 1000 µg/2 mL) during baseline and changed treatment 
to budesonide comparator (250 or 500 µg/2 mL) at the 
index prescription date. The budesonide reference cohort 
also included two groups of patients: initiation patients and 
continuation patients. Initiation patients were not prescribed 
corticosteroid nebulizers during baseline and received their 
first prescription for budesonide reference at the index pre-
scription date. The continuation patients were on budesonide 
reference (250, 500, or 1000 µg/2 mL) at baseline and 
continued treatment with budesonide reference at the index 
prescription date. The budesonide reference continuation 
patients may have been included more than once within 
the cohort with different index prescription dates if they 
satisfied the inclusion/exclusion criteria (see Inclusion and 
exclusion criteria section), including 2 years of continuous 
data (1 year before and 1 year after the index prescription 
date). However, the matching process ensured that only 
unique patients were randomly selected from all cohorts and 
included in the analyses.
The study period included a baseline period and an 
outcome period (Figure 1). The baseline period was 1 year 
before and including the index prescription date. The index 
prescription date was the date patients with no baseline 
budesonide nebulizer treatment received the first prescrip-
tion for reference or comparator budesonide (initiation 
patients), the date patients with baseline budesonide refer-
ence treatment received the first prescription for budesonide 
comparator (change patients), or the date patients with base-
line budesonide reference treatment continued budesonide 
reference prescriptions (continuation patients). The outcome 
period was the 1-year period following the index prescription 
date. The analysis included CDM data entered from Novem-
ber 2008 (FDA approval date of budesonide comparator in 
the US) until the last available data included in the CDM 
(September 2012) to ensure that the patient cohorts received 
treatment within a similar time frame.
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The study protocol was registered with the European 
Network of Centres for Pharmacoepidemiology and 
 Pharmacovigilance (ENCePP; ENCePP/SDPP/7648). The 
analyses and the dissemination of the results were conducted 
in accordance with the Respiratory Effectiveness Group 
(REG) standards21 and the ENCePP Code of Conduct.
Inclusion and exclusion criteria
Patients whose records were included in the analysis had a 
diagnosis for asthma using the International Classification of 
Diseases, Ninth Revision; Clinical Modification (ICD-9-CM; 
code 493 except codes 493.20–493.22 and 493.81), were 
aged 1–80 years (adult population: 12–80 years; pediatric 
population: ≥1 and <12 years), and had 2 years of continuous 
practice data, including 1 year prior to (baseline) and 1 year 
following (outcome) the index prescription date.
Patient records were excluded from the analysis if infor-
mation retrieved provided evidence of chronic respiratory 
diseases other than asthma (as determined by ICD-9 code, 
shown in Table S1) or evidence that patients had received 
prescriptions for inhaled corticosteroid (ICS) nebulizers other 
than budesonide reference in the baseline period. Use of other 
respiratory drugs, including use of ICS not delivered by a 
nebulizer device, during baseline was evaluated as a matching 
criterion, which is described in the Statistical analysis section.
Study population
Baseline demographic and clinical information collected 
for patients in the budesonide comparator or budesonide 
reference groups included age at the index prescription date 
for budesonide comparator or reference and gender; active 
comorbidities (presence of comorbid diagnoses; comorbidity 
score was calculated through the Charlson Comorbidity Index 
[CCI] using ICD-9-CM codes);22 active co-medication; pre-
vious respiratory therapy (including short-acting β
2
-agonist 
[SABA] and oral corticosteroids); ICS inhaler use (not deliv-
ered via nebulizer device), including number of prescriptions 
for ICS inhalers and daily dose of ICS inhalers during the 
baseline period; and number of clinical asthma exacerbations. 
Clinical asthma exacerbations were defined as exacerbations 
that included American Thoracic Society/European Respi-
ratory Society (ATS/ERS)-defined asthma exacerbations23 
(described in the Outcomes section) or required a course 
of antibiotic therapy for a lower respiratory event to allow 
1-year baseline period for patient
characterization and for confounder
and matching criteria definition
1-year outcome period for effectiveness
and safety evaluation
Budesonide comparator 
• Initiation: patients receive ≥1 first prescription
(including at the index prescription date)
• Change: patients receive ≥1 prescription
(including at the index prescription date) after
switching from budesonide reference in baseline 
• Initiation patients: patients not previously
prescribed ICS nebulizers
• Change/continuation patients: patients
with ≥1 prescription for budesonide
reference during baseline
Budesonide reference
• Initiation: patients receive ≥1 first prescription
(including at the index prescription date) 
Study period: 2 continuous years within the maximum period from November 2008 to September 2012
(1 year before launch of Budesonide Steri-Neb in the US up to the date of last available data).
• Continuationa: patients receive ≥1 continued
prescription (including at the index prescription
date)
Index prescription date=date at which patients receive
• First prescription for ICS nebulizer (either budesonide reference or budesonide
comparator) – initiation patients 
• First prescription for budesonide comparator – change patients
• Continued prescriptions for budesonide reference – continuation patients
Figure 1 Study design.
Notes: aPatients may be included more than once in the budesonide reference continuation patient group if their index prescription date satisfied the criterion of 2 years of 
continuous data (1 year before and 1 year after the index prescription date). However, during the matching process, it was ensured that only unique patients were analyzed. 
Abbreviation: ICS, inhaled corticosteroid.
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capture of asthma exacerbations that may have been confused 
for respiratory infection.24
Outcomes
The primary outcome was the rate of ATS/ERS-defined 
asthma exacerbations23 during the outcome period. ATS/ERS 
asthma exacerbations were defined as asthma-related emer-
gency department (ED) visits, inpatient hospitalizations, and/
or a prescription for an acute course of oral corticosteroids 
resulting from a lower respiratory event (diagnosis and proce-
dure codes are shown in Tables S2 and S3). Acute courses of 
oral corticosteroids were defined as all courses where dosing 
instructions suggest exacerbation treatment (eg, 6000, 5000, 
4000, 3000, 2000, 1000 reducing, or 30,000 mg as directed) 
and/or all courses unlikely to be maintenance therapy, ie, 
with no dosing instructions but recorded within a ±5-day 
window from a lower respiratory event. Lower respiratory 
events included asthma-related ED visits, hospital admissions, 
ambulatory visits, or respiratory investigations (Table S3).
Secondary outcomes included the rate of asthma-related 
hospitalizations (defined as ED visits or inpatient admis-
sions) and the rate of adverse events (AEs). The budesonide 
comparator and budesonide reference Summary of Product 
Characteristics (SPC)/Prescribing Information17,25 were used 
to generate a list of possible AEs to search for within the 
CDM database. The AEs identified in the database using 
the SPC-listed AEs serve as proxies for possible AEs. The 
presence of an AE within the database indicates that the 
patient had a consultation related to the AE. The SPC-listed 
potential AEs were identified in the database as ICD-9-CM 
codes. The AEs were classified by using the Medical Dic-
tionary for Regulatory Activities (MedDRA) system organ 
class (SOC) for comparison of the budesonide comparator 
and budesonide reference cohorts.
Statistical analysis
Pearson’s and Spearman’s correlation coefficients (as appropri-
ate) were calculated between all baseline variables to determine 
strengths of linear relationships between them. The correla-
tion coefficients were considered in conjunction with clinical 
interpretation to identify pairings of variables that may have 
presented co-linearity issues at the modeling stage. Where 
variables were considered to be co-linear, the most appropri-
ate variable in the pairing was selected, based on clinical and 
statistical interpretation. Multivariate analyses were carried 
out using the full dataset to identify baseline variables that 
were predictive (P<0.05) of outcomes. These were considered 
potential confounders when modeling the outcome variables.
Based on differences identified through exploratory 
analysis of baseline variables and predictive modeling of 
the baseline data in relation to the primary outcome variable 
(independent of treatment group), individual patients from the 
comparator and reference budesonide cohorts were matched 
to ensure the comparison of similar patients as in previous 
studies from our group.26,27 Exact matching for categorical 
variables and coarsened exact matching for numeric variables 
were used to match patients using 1:1 nearest neighbor match-
ing, without replacement. Budesonide reference initiation 
patients were matched with budesonide comparator initia-
tion patients, and budesonide reference continuation patients 
were matched with budesonide comparator change patients 
who switched from budesonide reference during baseline to 
budesonide comparator during the outcome period.
The exact matching approach was defined a priori and 
used a predefined set of key matching criteria rather than 
propensity score matching.21 Exact matching on clinically 
relevant variables was used to ensure that the comparator 
and reference patient cohorts would be treated similarly in 
clinical practice, given the emphasis on variables considered 
central to making treatment decisions. Thus, the compara-
tor and reference budesonide cohorts were characterized 
according to demographic characteristics; comorbidities; 
co-medications; prior respiratory therapy, including inhaler 
use; number of exacerbations; antibiotic treatment for lower 
respiratory events; and asthma control in the year prior to the 
index prescription date.
The final matching criteria included gender (male, 
female), age (<12±1 years; ≥12±5 years), average year of 
index prescription date (±1 year), exacerbations during the 
baseline period (0, 1, 2, and ≥3 years), and baseline prescribed 
SABA average daily dose (0, 1–100, 101–200, 201–400, and 
>400 mg), calculated as count of inhalers multiplied by doses 
in pack divided by 365 and multiplied by microgram strength. 
Additionally, patients were matched for asthma control in 
the year before their index prescription date for budesonide 
comparator or reference. Asthma control was defined using 
composite measures of key elements of asthma control from 
the database, as done previously.24,27,28 Risk-domain asthma 
control was defined as the absence of clinical asthma exac-
erbations (ie, no ATS/ERS-defined exacerbations and no 
prescription for antibiotics from a lower respiratory event) 
and no outpatient department visits. Overall asthma control 
was defined as risk-domain asthma control and average daily 
dose of ≤180 mg albuterol.
The power analysis was based on the finding from a previ-
ous study that 26.1% of asthma patients (2019 out of 7734) 
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using ICS had at least one exacerbation in the 1-year period 
after initiation.24 For the primary end point, the sample size 
required for adequate statistical power with a one-sided 0.05 
significance level was 2172 patients in each cohort. Previous 
randomized clinical trials evaluating the efficacy and safety 
of budesonide have reported a 20% difference between 
treatment groups to be clinically significant;29,30 to ensure a 
clinically significant outcome, a more stringent 15% limit was 
used in this study. Taken together, this enabled 90% power to 
show that there was no statistical difference between groups 
when the 95% confidence interval (CI) upper limit of mean 
difference in proportions between treatments was <15%.
For the primary outcome, non-inferiority for budesonide 
comparator vs reference was established if the 95% CI upper 
limit of mean difference in proportions between treatments 
in the rate of ATS/ERS-defined asthma exacerbations was 
<15%. Conditional Poisson regression models used empiri-
cal standard errors for more conservative CI estimations 
and adjusted for potential baseline confounders. Rates of 
exacerbations and AEs were compared between cohorts 
using conditional logistic regression models adjusted for 
potential baseline confounders and presented as rate ratios 
(RRs) with 95% CIs. Analyses are presented for the whole 
cohorts of budesonide comparator and budesonide reference, 
and sensitivity subanalyses are presented for the budesonide 
comparator and reference initiation patients only. Patient 
cohort placement was determined by one or more prescrip-
tions for either budesonide comparator or reference, and all 
study analyses were intention-to-treat analyses.
Results
Matching
The flow chart summarizing patient selection is shown in 
 Figure 2, and the cohort matching process is shown in Figure 3. 
The process was initiated with records of 37,468 patients who 
received budesonide reference and records of 65,519 patients 
who received budesonide comparator. After evaluation of 
records with inclusion/exclusion criteria, records of 17,393 
budesonide reference prescriptions (8780 unique patients) 
and 4450 patients treated with budesonide comparator were 
selected for matching. The matching process resulted in reten-
tion of records of 3109 patients who received budesonide refer-
ence and 3109 patients who received budesonide comparator.
Demographic and clinical characteristics of the matched 
budesonide reference and comparator cohorts during base-
line are summarized in Table 1 (baseline characteristics of 
the unmatched patient cohorts are shown in Tables S4–S6). 
The study population included mostly pediatric patients with 
the median age of 4 years for both cohorts. The majority of 
patients in both cohorts were males (61.1%) and had a diag-
nosis of allergic rhinitis (77%–81%). Approximately 23% of 
patients in both cohorts were prescribed SABAs. Prescrip-
tions for acute courses of oral corticosteroids during baseline 
occurred in ~10% of the budesonide comparator cohort and 
11% of the budesonide reference cohort. There were very 
few baseline AEs, likely due to the low median age of the 
population. No significant differences between cohorts were 
observed for baseline AEs by SOC or by individual AEs.
Baseline asthma control
In the year before and including the index prescription date 
for budesonide comparator or budesonide reference, risk-
domain asthma control and overall asthma control did not 
significantly differ between cohorts (Table 1). Risk-domain 
asthma control (ie, no clinical asthma exacerbations and no 
outpatient department visits) was shown in 29.3% (912/3109) 
of the budesonide comparator cohort and 29.3% (912/3109) 
of the budesonide reference cohort. Overall asthma control 
(ie, risk-domain asthma control and albuterol average daily 
dose ≤180 µg) was achieved in 28.1% (874/3109) of the 
budesonide comparator cohort and 28.4% (882/3109, P>0.1) 
of the budesonide reference cohort.
Effectiveness
ATS/ERS-defined exacerbations
The budesonide comparator was non-inferior to the 
budesonide reference for the primary outcome of rate of 
ATS/ERS-defined asthma exacerbations during the outcome 
period, with an adjusted upper 95% CI for the difference in 
proportions for budesonide comparator vs budesonide refer-
ence of 0.035 (3.5%) for the whole cohort analysis, which 
was below the non-inferiority criterion of <15%. For the 
sensitivity subanalysis of the initiation patients, the adjusted 
upper 95% CI for the difference in proportions for budesonide 
comparator vs budesonide reference also was 0.035 (3.5%).
Additionally, there was no significant difference in the rate 
of ATS/ERS-defined asthma exacerbations (adjusted RR=1.04, 
95% CI: 0.95–1.14) between the budesonide comparator and 
reference cohorts after adjustment for baseline confounders 
(Figure 4A). Most of the patients in each cohort (72.9% for 
budesonide comparator and 71.8% for budesonide reference) 
had no ATS/ERS-defined exacerbations. The sensitivity sub-
analysis of initiation patients was consistent with the whole 
cohort analysis and showed no significant difference between 
cohorts (adjusted RR=1.04, 95% CI: 0.95–1.14; Figure 4B). In 
the initiation patient groups, 72.9% of patients in the budesonide 
comparator group and 71.5% of patients in the budesonide 
reference group had no ATS/ERS-defined exacerbations.
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Patients with ≥1 prescriptions for
budesonide reference
A
N=37,468 unique patients and 80,114
prescription dates (Rx)
Inclusion criteria
Patients have received an
asthma diagnostic code
Patients received a
diagnosis for asthma
n=24,845 Rx
No other chronic
respiratory diagnosis
n=24,727 Rx
Age 1–80 years at
prescription date
n=24,727 Rx
No ICS nebulizer during
baseline
n=8926 patients
Patients with 2 years
continuous data
n=6039 patients
Patients with 2 years
continuous data
n=11,354 Rx
Patients received budesonide
nebulizer during baseline
n=15,408 Rx
Inclusion criteria
Patients have never
received another chronic
respiratory diagnostic code,
 excluding asthma
Exclusion criteria
Patients received a
nebulizer in baseline
(n=85 patients)
Initiate budesonide
reference
n=9011 patients
Continue budesonide
reference
n=15,716 Rx
Exclusion criteria
Patients do not have 2
years continuous data
(n=2887 Rx)
Exclusion criteria
Patients have received
an ICS nebulizer other
than budesonide reference
in baseline
(n=308 Rx)
Exclusion criteria
Patients aged <1 or >80 years at the 
date of prescription
(n=0)
Exclusion criteria
Patient observations where patients
have never received an asthma
diagnostic code
(n=55,269 Rx)
Exclusion criteria
Other chronic respiratory disease code
(n=118 Rx)
Exclusion criteria
Patients do not have 2
years continuous data
(n=4054 Rx)
Budesonide reference (n=17,393 Rxa)
Initiate (n=6039 patients)
Continue (n=11,354 Rx and 2744 patients)
Figure 2 (Continued) 
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Patients with ≥1 prescriptions for
budesonide comparator
N=65,519 patients
B
Inclusion criteria
Patients have received an
asthma diagnostic code
Patients received a
diagnosis for asthma
n=21,978
No other chronic
respiratory diagnosis
n=21,887
Age 1–80 years at
prescription date
n=21,887
No ICS nebulizer during
baseline
n=8872
Patients with 2 years
continuous data
n=3918
Patients with 2 years
continuous data
n=318
Budesonide
nebulizer during baseline
n=1565
Inclusion criteria
Patients have never
received another chronic
respiratory diagnostic code,
 excluding asthma
Exclusion criteria
Patients received an ICS
nebulizer in baseline
(n=166 patients)
Initiate budesonide
comparator
n=9038
Continue to budesonide
comparator
n=12,849
Exclusion criteria
Patients do not have 2
years continuous data
(n=4954)
Exclusion criteria
Patients have not received
budesonide reference
in baseline
(n=11,284)
Exclusion criteria
Patients aged <1 or >80 years at the 
date of prescription
(n=0)
Exclusion criteria
Patients have never received an asthma
diagnostic code
(n=43,541)
Exclusion criteria
Other chronic respiratory disease code
(n=91)
Exclusion criteria
Patients do not have 2
years continuous data
(n=1247)
Budesonide comparator (n=4450)
Initiate (n=3918 patients)
Change (n=318 patients)
Figure 2 Patient selection flow chart for patients whose records were included in the budesonide reference (A) and budesonide comparator (B) cohorts.
Notes: aPatients may be included more than once in the budesonide reference continuation patient group if their index prescription date satisfied the criterion of 2 years of 
continuous data (1 year before and 1 year after the index prescription date). The number of unique participants in the budesonide reference cohort is 8780.
Abbreviations: ICS, inhaled corticosteroid; Rx, prescription.
Asthma-related hospitalizations
The budesonide comparator and reference cohorts did not 
significantly differ in the rate of asthma-related hospitaliza-
tions during the outcome period (adjusted RR=1.10, 95% 
CI: 0.99–1.24) after adjustment for baseline confounders 
 (Figure 5A). There were no asthma-related hospitalizations 
in 77.9% of patients in the budesonide comparator cohort 
and 79.0% of patients in the budesonide reference cohort. 
The sensitivity subanalysis of the budesonide comparator and 
reference initiation patients was consistent with the whole 
cohort analysis and showed no significant difference between 
groups (adjusted RR=1.08, 95% CI: 0.96–1.22). There were 
no asthma-related hospitalizations in 77.9% of patients in the 
budesonide comparator initiation group and 79.1% of patients 
in the budesonide reference initiation group (Figure 5B).
Safety
Owing to the overall low numbers of AEs, RRs were not 
evaluated by SOC in the matched cohorts (AEs by SOC 
for unmatched patients are shown in Table S6). Instead, 
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Table 1 Demographic, clinical characteristics, and concomitant medications for the matched cohorts
Measure Matched cohortsa
Budesonide comparator 
(n=3109)
Budesonide reference 
(n=3109)
P-valueb
Year of date of index prescription
Median (IQR) 2010 (2009, 2010) 2009 (2009, 2010) <0.001
Age at index prescription date (years)
Median (IQR) 4 (2, 6) 4 (3, 6) <0.001
Distribution of patients among age categories, n (%)
Pediatric (1–11 years) 2841 (91.4) 2841 (91.4) N/A
Adults (≥12 years) 268 (8.6) 268 (8.6)
Gender, n (%)
Male 1900 (61.1) 1900 (61.1) N/A
Patients with rhinitis diagnosis, n (%)c
Yes 2402 (77.3) 2532 (81.4) <0.001
Patients with rhinitis diagnosis and/or received nasal spray, n (%)c
Yes 2448 (78.7) 2585 (83.1) <0.001
Patients available
Reference matched=17,393a
Comparator matched=4236
Gender
Reference matched=17,393
Comparator matched=4234
Clinical exacerbations
Reference matched=17,393
Comparator matched=4234
SABA daily dose
Reference matched=16,928
Comparator matched=4234
Age
Reference matched=13,255
Comparator matched=4216
Year of prescription date
Reference matched=11,364
Comparator matched=4063
Budesonide reference:budesonide comparator
1:1 uniquely matched patients
Budesonid reference=3109
Budesonid comparator=3109
Lost on matching
Reference patients (n=0)
Comparator patients (n=2)
Lost on matching
Reference patients (n=0)
Comparator patients (n=0)
Lost on matching
Reference patients (n=465)
Comparator patients (n=0)
Lost on matching
Reference patients (n=3673)
Comparator patients (n=18)
Lost on matching
Reference patients (n=1891)
Comparator patients (n=153)
Total lost on matching
Reference patients (n=14,284)
Comparator patients (n=1127)
Randomize matching patients*
*Software used to randomly pick
unique matched patients
Figure 3 Patient matching flow chart for patients whose records were included in the budesonide reference and budesonide comparator cohorts.
Notes: aPatients may be included more than once in the budesonide reference continuation patient group if their index prescription date satisfied the criterion of 2 years 
of continuous data (1 year before and 1 year after the index prescription date). Number of unique participants in the budesonide reference cohort is 8780. The matching 
process ensured that only unique patients were randomly selected from all cohorts and included in the analyses.
Abbreviation: SABA, short-acting β2-agonist.
(Continued)
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Table 1 (Continued)
Measure Matched cohortsa
Budesonide comparator 
(n=3109)
Budesonide reference 
(n=3109)
P-valueb
Patients with GERD diagnosis, n (%)c
Yes 654 (21.0) 803 (25.8) <0.001
Patients with GERD diagnosis who received GERD therapy, n (%)c
Yes 217 (7.0) 331 (10.6) <0.001
Patients with oral thrush (both diagnosis and received treatment), n (%)c
Yes 7 (0.2) 16 (0.5) 0.058
Patients who received paracetamol prescriptions, n (%)
Yes 257 (8.3) 380 (12.2) <0.001
Distribution of patients among CCI score categories, n (%)d <0.001
0 634 (20.4) 408 (13.1)
1–4 2341 (75.3) 2532 (81.5)
≥5 134 (4.3) 168 (5.4)
SABA inhalers daily dose (mg) in the year before index prescription date, 
categorized, n (%)e
N/A
0 2396 (77.1) 2396 (77.1)
1–100 616 (19.8) 616 (19.8)
101–200 22 (0.7) 22 (0.7)
201–400 36 (1.2) 36 (1.2)
≥401 39 (1.3) 39 (1.3)
Prescriptions for acute courses of oral corticosteroids in the year before index 
prescription date, categorized, n (%)f
0.136
0 2802 (90.1) 2756 (88.6)
1 176 (5.7) 232 (7.5)
2 67 (2.2) 49 (1.6)
≥3 64 (2.1) 72 (2.3)
Baseline ICS inhalers daily dose (mg), n (%)e <0.001
0 2847 (91.6) 2781 (89.4)
>1–100 244 (7.8) 299 (9.6)
101–200 14 (0.5) 17 (0.5)
201–400 3 (0.1) 7 (0.2)
≥401 1 (0.0) 5 (0.2)
Risk-domain asthma control in the year before index prescription date, n (%)g N/A
Controlled 912 (29.3) 912 (29.3)
Uncontrolled 2197 (70.7) 2197 (70.7)
Overall asthma control in the year before index prescription date, n (%)h 0.162
Controlled 874 (28.1) 882 (28.4)
Uncontrolled 2235 (71.9) 2227 (71.6)
Number of asthma ATS/ERS exacerbations, n (%) 0.746
0 2224 (71.5) 2214 (71.2)
1 596 (19.2) 623 (20.0)
2–3 236 (7.6) 226 (7.3)
≥4 53 (1.7) 46 (1.5)
Notes: aCohorts matched on gender, age (<12 [±1 year]; ≥12 [±5 years]), average year of index prescription date (±1 year), baseline “clinical” exacerbations (0, 1, 2, and 
≥3), and baseline SABA daily dose (categorized). bP-value based on conditional logistic regressions. cThrough GP visits in the study period (2008–2012). ICD-9 codes used 
for comorbidities: rhinitis, 472.0 or 477; GERD, 530.81; and oral thrush, 1120. dCalculated using the CCI (using ICD-9 codes) over the 1 year prior to and including the 
index prescription date. eDaily dose was calculated as count of inhalers multiplied by doses in pack divided by 365 and multiplied by microgram strength. fAll courses where 
dosing instructions suggest exacerbation treatment (eg, 6000, 5000, 4000, 3000, 2000, 1000 reducing, or 30,000 mg as directed) and/or all courses unlikely to be maintenance 
therapy, ie, with no dosing instructions but recorded within a ±5-day window from a lower respiratory event. gRisk-domain asthma control defined as the absence of asthma 
“clinical” exacerbation (ie, ATS/ERS exacerbation [asthma-related ED or inpatient hospital admission or prescription for an acute course of oral steroids from a lower 
respiratory event] or prescription for antibiotics from a lower respiratory event) and outpatient department attendance. hOverall asthma control defined as risk-domain 
asthma control and average daily dose of ≤180 µg albuterol.
Abbreviations: ATS/ERS, American Thoracic Society/European Respiratory Society; CCI, Charlson Comorbidity Index; ED, emergency department; GERD, gastroesophageal 
reflux disease; GP, general practitioner; ICD-9, International Classification of Diseases, Ninth Revision; ICS, inhaled corticosteroid; IQR, interquartile range; N/A, not 
available; SABA, short-acting β2-agonist.
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Figure 4 ATS/ERS-defined asthma exacerbations in the matched comparator and reference budesonide whole cohorts (A) and in the initiation patients (B).
Notes: Budesonide comparator and reference treatment cohorts matched for gender, age (<12 [±1 year]; ≥12 [±5 years]), average year of index prescription date (±1 year), 
baseline clinical asthma exacerbations (0, 1, 2, and ≥3), and baseline SABA daily dose (categorized). Whole cohorts analysis (A) adjusted for baseline exacerbations (ATS/ERS 
definition; categorized), age, and CCI score. Subanalysis of initiation patients (B) adjusted for baseline exacerbations (ATS/ERS definition; categorized) and age.
Abbreviations: ATS/ERS, American Thoracic Society/European Respiratory Society; CCI, Charlson Comorbidity Index; CI, confidence interval; RR, rate ratio; SABA, 
short-acting β2-agonist.
individual AEs were used for the whole cohort RR analy-
ses (Table 2; data for unmatched cohorts are provided in 
Table S6). The most frequent AEs during the 1-year outcome 
period were throat irritation (0.2% for budesonide comparator 
vs 0.4% for budesonide reference) and hoarseness/dysphonia 
(0.2% for each cohort). No significant differences between 
the treatment cohorts were found for the individual AEs. 
Additionally, there was no significant difference between the 
budesonide comparator and reference cohorts in the report 
of any AE (combined across individual AEs) for the whole 
cohort analysis (adjusted RR=0.71, 95% CI: 0.27–1.85, 
adjusted for age, year at index prescription date (±1 year), 
gastroesophageal reflux disease (GERD) diagnosis/therapy, 
and categorized CCI score) or the sensitivity subanalysis of 
initiation patients (adjusted RR=0.62, 95% CI: 0.23–1.65, 
adjusted for average year of index prescription date (±1 year), 
GERD diagnosis/therapy, and categorized CCI score) after 
adjustment for baseline confounders.
Discussion
Following matching of the patients included in the budesonide 
comparator and budesonide reference cohorts, assessment of 
effectiveness indicated no significant difference between 
cohorts for ATS/ERS-defined asthma exacerbations. The 
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budesonide comparator was shown to be non-inferior to the 
budesonide reference in the rate of asthma exacerbations. 
The sensitivity subanalysis of the budesonide comparator and 
reference initiation patients was consistent with the whole 
cohort analysis. Furthermore, the rate of asthma-related hos-
pitalizations and AEs did not significantly differ between the 
budesonide comparator and budesonide reference cohorts. As 
noted previously, reducing exacerbations and hospitalizations 
due to exacerbations are both important treatment goals for 
patients with asthma.18,19,31
Approaches generally similar to the methods of the cur-
rent study, but with different disease states, have been used 
to compare branded and generic forms of a given medication, 
and these most often involve assessment of patients who were 
switched from branded to generic treatments.32,33 However, 
this approach has also been used to evaluate patients treated 
only with either the branded or generic form of a given 
medication.34 The present study used a hybrid of these two 
types of designs to examine non-inferiority of effectiveness 
of budesonide comparator vs budesonide reference and to 
examine safety through AE rates. A key aspect of the historical 
analysis design was patient matching, and this method is often 
used in case–control studies to allow more reliable compari-
sons between treatments being evaluated.35 The present study 
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Figure 5 Asthma-related hospitalizations in the matched comparator and reference budesonide whole cohorts (A) and in the initiation patients (B).
Notes: Budesonide comparator and reference treatment cohorts matched for gender, age (<12 [±1 year]; ≥12 [±5 years]), average year of index prescription date (±1 year), 
baseline clinical asthma exacerbations (0, 1, 2, and ≥3), and baseline SABA daily dose (categorized). Whole cohorts analysis (A) adjusted for baseline hospitalizations 
(categorized) and paracetamol use. Subanalysis of initiation patients (B) adjusted for baseline hospitalizations (categorized) and paracetamol use.
Abbreviations: CI, confidence interval; RR, rate ratio; SABA, short-acting β2-agonist.
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used exact matching, which, compared to other methods, such 
as propensity score matching, has the advantage of pairing 
patients on key measures of clinically relevant interest, such 
as demographics and disease severity. Matching minimizes 
the potential influence of measurable confounders.35
Clinical trials that evaluated budesonide inhalation 
suspension in patients with asthma have demonstrated that 
this agent is effective for preventing asthma exacerbations 
and asthma-related hospitalizations.9,36 These end points are 
particularly important in patients with asthma, both clini-
cally and economically. It has been estimated that in-hospital 
asthma mortality in patients aged >5 years hospitalized for 
asthma exacerbations is 0.5% and that these deaths account 
for one-third of all asthma deaths reported in the US.19 The 
mean cost per hospital stay due to exacerbations in 2006 
was $9078.19 It has also been reported that the occurrence 
of severe exacerbations is correlated with the progression of 
irreversible airflow limitation over time, suggesting that the 
transient intense airway inflammation and excess broncho-
constriction characteristic of these events potentially play a 
role in progressive changes in airway structure and function, 
leading to irreversible airflow limitation.37
Strengths of the current study include the examination of 
real-life treatment outcomes in patients with asthma within 
a large database of commercially insured patients in the US. 
Studies that examine real-life clinical database treatment 
outcomes are an important complement to the findings from 
randomized clinical trials that typically enroll highly selected 
patient populations, thereby limiting the generalizability of 
the trial findings.38,39 Real-life clinical database studies, such 
as the current study, enroll large, diverse patient populations 
that represent actual clinical practice treatment management 
that is generalizable to a broader population of patients. The 
current study was conducted according to REG methodologi-
cal standards.21 To ensure patients were characterized using 
all potentially relevant variables and that the central outcomes 
of interest could be assessed, the plan for statistical analysis, 
the study population, and the asthma-related outcomes of 
interest were determined prior to any analysis of the database. 
Furthermore, the large database allowed matching of patient 
cohorts on baseline potential confounding variables.
As with all database studies, there are limitations associ-
ated with internal validity and possible confounding factors. 
Additionally, there is a possibility of coding inconsistencies 
or errors, although differential effects on the cohorts are 
not expected. The patients examined in the study received 
commercial insurance associated with employment, and 
caution should be taken if generalizing findings to patients 
who receive government-provided health care, such as Med-
icaid. Additionally, characteristics of the patient population 
included in this real-world study may limit generalization of 
study findings to adults or patients with frequent exacerba-
tions. The AEs reported in the current study were selected 
from the budesonide comparator and reference SPC and are 
substitutions for potential AEs. The actual AEs in response 
to treatment cannot be specifically identified in the database. 
Instead, the reported AEs indicate that the patient had a 
consultation related to the AE, but whether the treatment or 
another underlying condition resulted in the AE is not known. 
Thus, although the AE rates reported in the current study were 
low, they are likely to be overreported. Consistent with a real-
world approach and safety analysis, the patient cohorts were 
derived using intention-to-treat analyses based on one or more 
prescriptions for either budesonide comparator or reference. 
While allowing examination of a real-life varied respiratory 
cohort, this approach may have attenuated differences in 
Table 2 AEs in the matched cohorts
Individual AEs, n (%) Matched cohortsa
Budesonide comparator 
(n=3109)
Budesonide reference 
(n=3109)
P-valueb
Throat irritation 6 (0.2) 12 (0.4) 0.144
Hoarseness/dysphonia 6 (0.2) 6 (0.2) 1.000
Bronchospasm/paradoxical bronchospasm 2 (0.1) 1 (0.0) 0.571
Cutaneous hypersensitivity reactions (rash, urticaria) 2 (0.1) 0 (0.0) 0.969
Candidiasis of the mouth and throat 1 (0.0) 1 (0.0) 1.000
Growth retardation in children 1 (0.0) 1 (0.0) 1.000
Anaphylactic reactions 0 (0.0) 0 (0.0) 0.967
Anxiety 0 (0.0) 3 (0.1) 0.962
Depression 0 (0.0) 2 (0.1) 0.969
Insomnia 0 (0.0) 1 (0.0) 0.967
Notes: aCohorts matched on gender, age (<12 [±1 year]; ≥12 [±5 years]), average year of index prescription date (±1 year), baseline clinical asthma exacerbations (0, 1, 2, 
and ≥3), and baseline SABA daily dose (categorized). bP-value based on conditional logistic regressions.
Abbreviations: AEs, adverse events; SABA, short-acting β2-agonist.
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outcomes between cohorts. Given the inherent limitations 
of database studies even with matched treatment groups, 
the study results should be viewed in conjunction with those 
from other reports, particularly randomized controlled trials.
Conclusion
In this real-life, matched cohort study, the budesonide com-
parator met the non-inferiority criterion for asthma exacer-
bation rates, as defined by ATS/ERS criteria. Additionally, 
there were no differences between comparator or reference 
budesonide for rates of asthma-related hospitalizations or 
AEs. Therefore, the budesonide comparator is an effective 
treatment option for prevention of asthma exacerbations. 
Given the high costs associated with the management of 
persistent asthma, the availability of the budesonide com-
parator as a lower cost generic treatment alternative with 
equivalent effectiveness provides potential economic benefit 
in reducing the cost of asthma care.
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